このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

GLOW: 性別適合ケアと精神的健康:生活の質、職業生活、医療成果に関する縦断的研究 (GLOW)

2026年9月25日 更新者:Region Skane

GLOW:性別適合医療とメンタルヘルス:生活の質、仕事生活、および医療成果に関する縦断的研究

Gender-Affirming Care and Mental Health (GLOW) investigates the psychological, medical, and social factors that influence the outcomes of gender-affirming care, as well as its impact on mental health, work capacity, and quality of life. Gender dysphoria is defined as the incongruence of a person's experienced gender and sex assigned at birth. In Sweden, the prevalence of gender dysphoria has increased significantly in recent decades. Still there is no consensus on the long-term outcomes ofgender-affirming care. 1. What are the baseline characteristics in individuals seeking gender-affirming care and do any of these predict outcomes of gender-affirmative care?2. Do individuals with gender dysphoria experience improved or reduced quality of life, gender congruence, or functional capacity after gender-affirming care?3. Does gender-affirming care reduce or increase psychiatric symptoms and self-concept clarity?4. What are the effects of gender-affirming care on mortality, work capacity, and healthcare resource utilization as compared to an age and gender matched control group?Data and MethodGLOW targets patients at the Gender Dysphoria Clinic, Region Skåne and Linköping a National Highly Specialized Care unit (NHV). Mixed methods will be used to analyze data from national registries and self-reported assessments.The NHV status ensures standardized high-quality data collection and clinical follow-up, making this project a unique opportunity to evaluate the care given to individuals with gender dysphoria.Societal Relevance and Utility The growing demand for gender-affirming care underscores the need for research to identify the most effective interventions. The results may also help reduce stigma and improve social integration for individuals with genderdysphoria.GLOW is a longitudinal mixed-methods study based at the NHV Gender Dysphoria Clinic in Region Skåne. It includes registry-based, qualitative interviews and repeated self-report measures up to 5 years after baseline assessment. Quantitative analyses will include regression models and Bayesian methods.

調査の概要

状態

募集

詳細な説明

The GLOW study is a longitudinal investigation designed to evaluate the effects of gender-affirming care on the well-being of individuals diagnosed with gender dysphoria in Sweden. Grounded in an interdisciplinary framework, the study adopts a mixed-methods approach to integrate quantitative registry data and longitudinal self-assessments with in-depth qualitative interviews. This design allows for anunderstanding of the medical, psychological, and social dimensions of gender-affirming care beyond the limitations of cross-sectional studies.The project is embedded in Linköping and Region Skåne's National Highly Specialized Care (NHV) unit, ensuring standardized data collection and uniform clinical procedures across participants. Thus, the study benefits from a stable clinical infrastructure and reliable access to a diverse cohort undergoing gender-affirming assessment and treatment. In addition, national health and population registries provide extensive data for long-term follow-up, including health service utilization, prescription records, socio-economic indicators, and mortality data.GLOW is commited to a collaborative research practice. The project actively involves key stakeholders-healthcare professionals, policymakers, and patient advocacy groups such as Transammans and RFSL. Their input ensures that the study remains aligned with real-world clinical needs and community priorities, enhancing its relevance.The study is conceptually anchored in the Biopsychosocial Model and draws on Minority Stress Theory, Self-Concept Clarity Theory, and Gender Affirmation Theory. These frameworks support the exploration of how social stressors, identity development, and access to affirming care interact to shape mental health trajectories. This theoretical integration provides a solid foundation for interpreting variability in treatment response and quality-of-life outcomes.Statistical modeling will be employed to complement traditional analyses, offering probabilistic interpretations and greater flexibility in handling complex longitudinal data structures. Qualitative interviews will be analyzed using thematic methods, with findings triangulated against quantitative trends to increase the validity and depth of insights.While many existing studies on gender-affirming care focus on short-term or medical outcomes, GLOW takes a broader and longer-term perspective. It includes economic implications, healthcare resource use, work life outcomes, and subjective experiences of identity and social integration. This holistic approach will generate knowledge applicable to clinical care, policy formulation, and public health planning.Finally, the project emphasizes sustainability. Infrastructure and data collection protocols have been designed to support extended follow-up. In doing so, GLOW aims to contribute not only to scientific literature but also to the development of evidence-based guidelines and inclusive healthcare systems.

Research Questions Taken together, understanding the trajectories of gender dysphoria is crucial. Such research can help determine which individuals benefit most from gender-affirming care and who might dropout during the process or experience dissatisfaction post-transition. Adapting current services to meet individual needs is essential. The current project will employ both quantitative and qualitative methods integrated into the clinical practice at the Gender Dysphoria Clinic, Region Skåne a National Highly Specialized Care unit (NHV), along with information from relevant databases and registries to achieve this goal.

  1. What are the baseline characteristics in individuals seeking gender-affirming care and do any of these predict outcomes of gender-affirmative care?
  2. Do individuals with gender dysphoria experience improved or reduced quality of life, gender congruence, or functional capacity after gender-affirming care?
  3. Does gender-affirming care reduce or increase psychiatric symptoms and self-concept clarity?
  4. What are the effects of gender-affirming care on mortality, work capacity, and healthcare resource utilization as compared to an age and gender-controlled comparison group?

研究の種類

観察的

入学 (推定)

500

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Malmö
      • Malmö、Malmö、スウェーデン
        • 募集
        • The Gender Dysphoria Clinic at Skåne University Hospital, Malmö, Sweden
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

なし

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Participant recruitment will take place at the NHV Gender Dysphoria Clinic in Malmö, Region Skåne, which is one of Sweden's national centers for the diagnosis and treatment of gender dysphoria.

説明

Inclusion Criteria:

  • All adults (18+) referred to the NHV clinic for gender dysphoria assessment in Region Skåne.

Exclusion Criteria:

  • Inability to read/write Swedish
  • Protected identity status

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
性別違和

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Quality of Life
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

World Health Organization Disability Assessment Schedule (WHODAS 2.0) to evaluate general health status and functioning.

Score is converted to a 0-100 scale, where a higher score indicates greater disability or limitation in functioning.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Generalized Anxiety Disorder Scale (GAD-7)
時間枠:At the beginning of the clinical assessment, end of the assessment (usually 1 year after start), at 24 months and 60 months.

Generalized Anxiety Disorder Scale (GAD-7). The range of GAD 7 is 0 to 21. Higher scores indicate greater severity of anxiety symptoms.

At the beginning of the clinical assessment, end of the assessment (usually 1 year after start), at 24 months and 60 months.
Substance use
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.

AUDIT produces a score from 0 to 40, with higher scores indicating a greater likelihood of hazardous, harmful, or dependent drinking.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.
Substance use
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.

Measured using the Drug Use Disorders Identification Test (DUDIT). DUDIT produces a score from 0 to 44, with higher scores indicating more severe drug-related problems or potential dependence.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.
Self-Concept Clarity and Identity Functioning
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.

Measured via the Self-Concept and Identity Measure (SCIM) and Level of Personality Functioning Scale - Brief Form 2.0 (LPFS 2).

SCIM has a total score range from 36 to 180, with higher scores indicating greater identity disturbance, LPFS has a range of 12 to 48, where a higher score indicates greater dysfunction.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.
Change in Mental Health Symptoms
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Measured using the Generalized Anxiety Disorder Scale (GAD-7). The range of GAD 7 is 0 to 21. Higher scores indicate greater severity of anxiety symptoms.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months
Change in Mental Health Symptoms
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Questions regarding number of suicidal behavior.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months
Gender Congruence and Life Satisfaction
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Measured using the Gender Congruence Life Satisfaction Scale (GCLS). Range is 0 to 50. A higher score indicates a more positive outcome (higher gender congruence, better gender-related mental well-being, and better general life satisfaction).

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months
Mortality
時間枠:60 months

Source: Cause of Death Register (CDR)

60 months
Work Capacity and Socioeconomic Participation
時間枠:Baseline and 60 months

Derived from the Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA), including employment status and income.

Baseline and 60 months
Healthcare Utilization
時間枠:Baseline and 60 months

Source: National Patient Register (NPR) Metrics: Number of hospital visits.

Baseline and 60 months
Healthcare Utilization
時間枠:Baseline and 60 months

Source: Prescribed Drug Register Metrics: Use of medications (number of doses)

Baseline and 60 months
Healthcare Utilization
時間枠:Baseline and 60 months.

Source: National Patient Register (NPR) Metrics: Psychiatric diagnoses.

Baseline and 60 months.
EQ5d
時間枠:Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

The EuroQol 5-Dimension (EQ-5D) assesses health-related quality of life. In the EQ-5D, each response generates a single-digit code between 1 and 5, where 1 = no problems and 5 = extreme problems. These single-digit codes can be combined to form a five-digit code corresponding to a specific health profile. Each dimension has five possible responses, meaning that together they can generate 3,125 different health profiles.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月1日

一次修了 (推定)

2030年12月1日

研究の完了 (推定)

2030年12月1日

試験登録日

最初に提出

2026年3月13日

QC基準を満たした最初の提出物

2026年3月13日

最初の投稿 (実際)

2026年3月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2024-07577-02

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する